On July 17, GenFleet Therapeutics-B fell 8.2% in regular trading, trading at HK$35.88/share, with turnover of HK$38.47 million.

The decline came as the broader biotechnology sector faced significant selling pressure. Among sector peers, Akeso fell 11.79%, 3SBio fell 11.45%, SKB Bio fell 5.68%, Innovent Bio fell 5.41%, and BeiGene fell 2.83%.

The pullback follows two consecutive days of sharp gains. On July 15, the company announced a placement of 13.6 million new H shares at HK$34.69 per share, representing a 9.71% discount to the July 14 closing price. The placement, arranged through Morgan Stanley Asia and CLSA, is expected to raise net proceeds of approximately HK$467 million, with 75% earmarked for advancing core RAS inhibitor programs including GFH276, GFS202A, and GFS784. The stock surged over 7% on July 15 and gained a further 10.36% on July 16 before retreating with the sector-wide selloff.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)